(Q84140005)
Statements
Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies (English)
C Harrington
S Sawchak
C Chiang
J Davies
C Donovan
A M Saunders
M Irizarry
B Jeter
M Zvartau-Hind
C H van Dyck